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Abstract
Pyoderma gangrenosum (PG) is a rare noninfectious neutrophilic dermatosis. Clinically it starts
with sterile pustules that rapidly progress and turn into painful ulcers of variable depth and size with
undermined violaceous borders. The legs are most commonly affected but other parts of the skin
and mucous membranes may also be involved. Course can be mild or malignant, chronic or
relapsing with remarkable morbidity. In many cases PG is associated with an underlying disease,
most commonly inflammatory bowel disease, rheumatic or haematological disease and malignancy.
Diagnosis of PG is based on history of an underlying disease, typical clinical presentation,
histopathology, and exclusion of other diseases that would lead to a similar appearance. The peak
of incidence occurs between the ages of 20 to 50 years with women being more often affected than
men. Aetiology has not been clearly determined yet.
The treatment of PG is a challenge. Randomized, double-blinded prospective multicenter trials for
PG are not available. The best documented treatments are systemic corticosteroids and ciclosporin
A. Combinations of steroids with cytotoxic drugs are used in resistant cases. The combination of
steroids with sulfa drugs or immunosuppressants has been used as steroid-sparing modalities. Anti-
tumor necrosis alpha therapy in Crohn's disease showed a rapid response of PG. Skin transplants
and the application of bioengineered skin is useful in selected cases as a complement to the
immunosuppressive treatment. Topical therapy with modern wound dressings is useful to minimize
pain and the risk of secondary infections. Despite recent advances in therapy, the prognosis of PG
remains unpredictable.
Disease name
Pyoderma gangrenosum
Definition/Diagnostic criteria
Pyoderma gangrenosum (PG) is a primarily sterile inflam-
matory neutrophilic dermatosis. It is characterized by
recurrent cutaneous ulcerations with mucopurulent or
hemorrhagic exudate. These very painful ulcers present
with undermined bluish borders with surrounding ery-
thema. In many cases, PG is associated with inflammatory
bowel disease, rheumatic disorder or neoplasia [1-3].
Powell et al. [4] suggested a classification of PG into four
major clinical types [see Table 1].
Epidemiology
Accurate epidemiological data on PG are missing. The
peak of incidence occurs between the ages of 20 to 50
years with women being more often affected than men
[2,6]. Cases in infants and adolescents account for only
4% of PG. PG in elderly people has occasionally been
reported [7]. The general incidence has been estimated to
be between 3 and 10 per million per year [8].
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Clinical presentation
PG occurs most commonly on the lower legs with prefer-
ence for the pretibial area [Fig. 1 &2]. PG has been
reported on other sites of the body as well, including
breast, hand, trunk, head and neck, and peristomal skin
[Fig. 3 &4]. Extracutaneous manifestations include
involvement of upper airway mucosa, eye [9-12], genital
mucosa [13], sterile pulmonary neutrophilic infiltrates
[14] or spleen infiltrates [15], and neutrophilic myositis
[16]. Sterile cortical osteolysis has been observed adjacent
to PG ulcers as another extracutaneous manifestation of
the disease [17].
The development of PG is a feared complication after
breast surgery and other surgical procedures [18-20]. It
seems to me that areas rich in subcutaneous fat tissue bear
a somewhat higher risk than others but systematic investi-
gations in this field are missing.
The ulcer starts as a follicular pustule with rapid growth,
tissue necrosis and enlargement of the area. The surround-
ing skin is erythematous with infiltration end oedema.
The ulcer borders are typically undermined and viola-
ceous or bluish [Fig. 1]. The ulcers develop a purulent
cover, which rapidly becomes malodorous due to second-
ary infection. A strong sensation of pain often is associ-
ated to PG [1,2,10].
In larger series, about 50% of patients show an underlying
disorder. Ulcerative colitis is found in 10–15% of cases.
Another associated disease is Crohn's regional enteritis
with a frequency close to that of ulcerative colitis
[2,21,22]. On the other hand, less than 3% of patients
with Crohn's disease or ulcerative colitis develop PG
[23,24]. Hepatitis C, seronegative rheumatoid arthritis,
spondylitis, and a broad spectrum of lymphoproliferative
disorders including monoclonal gammopathies, leukae-
mia, lymphoma, and myelodysplastic syndrome have
been described in association with PG [2,4,25,26].
The PG-ulcers associated with arthritis seem to have a
poorer prognosis than others. In a study covering 2 years
78.9% of PG-ulcers in general healed versus only 23.4%
in arthritis-associated PG [27]. In such cases PAPA syn-
drome has to be considered [28]. PG involvement of the
hands shows a higher percentage of lymphoproliferative
than chronic inflammatory bowel disease [29].
PG is a typical clinical presentation of the PAPA syndrome
also known as familial recurrent arthritis [28]. The auto-
somal dominant inherited disease is characterized by
nonaxial destructive arthritis, severe cystic acne and PC.
PAPA syndrome is caused by mutations in the PSTPIP1
gene on chromosome 15 involved in regulation of inflam-
matory response [30].
PG can arise as a consequence of drug therapies. Recent
examples of drug-induced PG include compounds such as
propylthiouracil [31], pegfilgastrim – a granulocyte-stim-
ulating factor [32], and gefinib – an inhibitor of epider-
mal growth factor receptor [33].
Etiology and pathogenesis
PG was initially thought to be caused by bacterial infec-
tion in the immunocompromised host [1]. Fulbright et al.
[20] hypothesized that PG results from an aberrant
immune response to yet unidentified factors. Depositions
of proteins in skin vessels in PG lesions have suggested an
Arthus-like reaction [34]. Since inflammatory bowel dis-
ease is the most common underlying disorder, cross-react-
ing antigens in the bowel and the skin could be
responsible for secondary cutaneous manifestation [2].
Cellular analysis in PG demonstrated aberrant integrin
oscillations on neutrophils and aberrant neutrophil track-
ing of patients with PG [35,36]. Pathways to protect the
epidermis from neutrophil infiltration seem to be insuffi-
cient in PG resulting in tissue necrosis.
Diagnostic methods
Diagnosis of PG relies on clinical signs first and is sup-
ported by biopsy for histopathology. Knowledge of the
patient's history for possible underlying disease and spe-
cific investigations based on that background are neces-
sary. Therefore diagnosis is made by exclusion of other
possible disorders. No laboratory parameter for PG is
available. The histopathology of PG is nonspecific and
changes with the stage of lesion. The initial lesions show
Table 1: The different clinical types of PG
Clinical variants Typical findings
Ulcerative PG Ulceration with rapidly evolving purulent wound ground
Pustular PG Discrete pustules, sometimes self-limited, commonly associated with inflammatory bowel disease
Bullous PG Superficial bullae with development of ulcerations
Vegetative PG Erosions and superficial ulcersOrphanet Journal of Rare Diseases 2007, 2:19 http://www.OJRD.com/content/2/1/19
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a deep suppurative folliculitis with dense neutrophilic
infiltrate. In about 40% of cases, leukocytoclastic vasculi-
tis is present. PG with [necrotizing] granulomatous
inflammation has been described [3,34,37]. These reports
illustrate the difficulties of a diagnosis based solely on his-
topathology since concomitant occurrence of PG and sys-
temic necrotizing vasculitis has been observed.
Differential diagnosis
Six disease categories may imitate the clinical appearance
of PG [38]:
(a) Vascular occulusive or venous disease including cal-
ciphylaxis which is particular painful and rapidly evolv-
ing.
(b) Vasculitis. That is a particular challenge when PG
develops in a patient with vasculitic rheumatoid arthritis.
Differential diagnoses of this topic include Wegener's dis-
ease, phospholipid syndrome, or in Adamantiades-Beh-
cet's disease etc.
(c) Cancer. Again the differential diagnosis is most com-
plicated in patients with lymphomas or leukaemia. Where
the specific cutaneous lesions may present as suppurative
ulcers.
(d) Infectious disease. Ecthymata and deep [tropical]
mycoses like sporotrichosis may resemble PG. The rapid
onset of post-surgical PG often reminds of acute deep skin
infection such as erysipelas or gangrene [18]. Late syphilis
has become more common again and may develop sup-
purative ulcerations. Deep viral herpetic infections can
resemble PG.
(e) Exogenous tissue injury. Facticious panniculitis as a
part of the Münchhausen syndrome may masquerading as
PG [39]. Insect or spider bites can cause necrotizing skin
ulcers.
(f) Drug reactions. Pustular drug reactions may masquer-
ade as pustular PG.
Treatment
Systemic therapy
For patients with a more widespread disease or rapidly
progressive course, systemic treatment is mandatory. Cor-
ticosteroids, like prednisolone, 1 to 2 mg per kg per day,
are widely used for initial therapy [2,4,25]. Trying an ini-
tial high-dose therapy aims to prevent progression and
rapidly stop inflammation. Action of pulse therapy with
suprapharmacological doses of corticosteroids [1 g of
methylprednisolone] is faster [40]. Since this treatment
may cause fatal side effects in patients with cardiovascular
disease on diuretics, patients have to be carefully selected.
Ciclosporin A is an inhibitor of T-lymphocyte activation.
Immunosuppressive therapy with ciclosporin A has
become an accepted treatment for widespread PG after
initial steroids or in combination with steroids. In many
cases, steroids can be completely be replaced by
ciclosporin A [41,42]. Doses of 2 to 3 mg ciclosporin A/kg
body weight and day show efficacy in PG [43]. During
therapy with ciclosporin A it is necessary to control blood
pressure and creatinine. The drug induces an early
response but has no impact on the incidence of recur-
rences [44]. Therefore, combination with other drugs can
become necessary even after initial response to
ciclosporine A monotherapy.
Sulfa drugs are useful in milder cases of PG. The combina-
tion of steroids with diaminodiphenylsulfone [dapsone]
up to 200 mg daily [only for patients with a normal glu-
cose-6-phosphate dehydrogenase level] is the most popu-
lar. Dapsone inhibits neutrophil migration and
production of reactive oxygen species and exerts a variety
of other anti-inflammatory activities [4,45]. Formation of
Acute rapid growing pyoderma gangraenosum with under- mined violaceous borders Figure 1
Acute rapid growing pyoderma gangraenosum with under-
mined violaceous borders.Orphanet Journal of Rare Diseases 2007, 2:19 http://www.OJRD.com/content/2/1/19
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met-hemoglobin needs regular monitoring during this
treatment.
Clofazimine is a scavenger of hypochlorus acid, thus
reducing the chlorination of proteins by neutrophils. It
stimulates phagocytosis and superoxide production and
has a direct antibacterial activity as well. In my opinion
the efficacy of clofazimine 300 to 400 mg/day is compara-
ble to that of sulfa drugs as dapsone. A common side effect
is hyperpigmentation [46].
Thalidomide shows immunomodulatory activity such as
suppression of tumour necrosis factor-alpha, basic fibrob-
last growth factor and neutrophil chemotaxis. It was used
in combination with steroids [47]. Thalidomide is tera-
togenic and therefore absolutely contraindicated in fertile
women.
Colchicine, an inhibitor of the spindle-apparatus with
anti-inflammatory properties, was employed in two
patients with PG from Greece [48]. It may be used as a sin-
gle agent or in combination with prednisolone depending
on the severity of disease. Gastrointestinal adverse effects
may limit its use.
Azathioprine [100–150 mg/day] is a cytotoxic drug usu-
ally administered for its steroid-sparing effects. Its action
is delayed of at least about 2 to 4 weeks. Blood counts and
transaminases should be monitored [2,4,45]. There is a
wide inter-individual variability in azathioprine metabo-
lism due to a common genetic polymorphism of thiopu-
rine methyltransferase, a major metabolizing enzyme of
azathioprine. Azathioprine and sulfasalazine are a good
choice when the underlying disease is ulcerative colitis or
Crohn's disease.
Another cytotoxic drug that has been used in PG is cylo-
phosphamide. Cyclophosphamide pulse therapy fol-
lowed by either azathioprine or methotrexate is an
effective treatment in steroid-refractory Crohn's disease.
In cases of Crohn's associated PG may achieve long term
remissions with this regimen lasting for up to 30 months
[49].
Mycophenolate mofetil is an inhibitor of the purin syn-
thesis selectively reducing the proliferation of T- and B-
lymphocytes. With the dosage of 2 g/day there is a very
low risk of renal and hepatic side effects. Mycophenalate
mofetil was used in peristomal PG and other refractory
cases [50,51]. Recently, a case of staphylococcal and pseu-
domonal sepsis has been reported in a mycophenolate
mofetil treated PG-patient [52].
Enteric-coated mycophenolate sodium [ECMPS] is an
advanced formulation delivering mycophenolic acid. At a
dosage of 720 mg ECMPS exhibits equivalent mycophe-
nolate acid exposure to mycophenolate mofetil 1000 mg.
Recent trials demonstrated that ECMPS has a similar
safety profile than mycoephenolate mofetil [53].
Postsurgical pyoderma gangraenosusm [a] before treatment; [b] after immunosuppressive treatment with oral prednisolone  and mesh-graft transplantation Figure 2
Postsurgical pyoderma gangraenosusm [a] before treatment; [b] after immunosuppressive treatment with oral prednisolone 
and mesh-graft transplantation.Orphanet Journal of Rare Diseases 2007, 2:19 http://www.OJRD.com/content/2/1/19
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Tumour necrosis alpha inhibitor infliximab was reported
to be effective in PG associated with inflammatory bowel
disease at a dosage of 5 mg/kg body weight. Infliximab is
given by infusion at weeks 0, 2 and 6, and every 8 weeks
thereafter. The chimeric antibody is usually combined
with low-dose methotrexate for Crohn's disease [54,55].
In a small series including 4 patients with fistulating
Crohn's disease and PG infliximab was given either as a
single infusion or a series of three infusions at a dosage of
5 mg per kg body weight/day. All patients demonstrated a
rapid healing of PG within 4 weeks after starting the treat-
ment. Healing was complete and relapses were not
observed [56]. In another study four patients with PG-
ulcers and Crohn's disease showed a marked improve-
ment after a single infusion of infliximab [57]. Since infu-
sion reactions can occur in 3% to 17% of patients with
Crohn's disease that are antibody associated the concur-
rent administration of steroids and the use of immuno-
suppressant like methotrexate or azathioprine has been
recommended [58].
The positive effect on PG has also seen with another
tumour-necrosis factor alpha antagonist etanercept, a
fusion protein [59]. Etanercept is applied by subcutane-
ous injections of 50 mg twice weekly. Because there is a
risk of reactivation of tuberculosis during anti-tumour
necrosis alpha therapy patients have to be screened for
tuberculosis before and during treatment [58].
Tacrolimus, a selective calcineurin inhibitor, was used at
low dosages of 0.1 mg per kg body weight/day. The treat-
ment was monitored to maintain a serum level of between
4 and 6 ng/L. Complete clearance of skin lesions was
observed in two patients with underlying ulcerative colitis
[60].
Since PG is a neutrophilic disease, removal of activated
neutrophiles should improve the symptoms. Leukocyta-
pheresis, where white blood cells are removed extracor-
poreal, and granulocyte adsorptive apheresis, a more
selective procedure, have been used in single cases with
success. These methods have been used in single cases
unresponsive to systemic standard therapy with success
[61,62].
Topical therapy
Topical treatment is important in any case when ulcers
have developed. Moist wound management is a corner-
stone of wound management. Since most ulcers show
heavy exudates, foam dressings or laminate dressings
composed of different layers are recommended. In case of
sloughy or purulent covered lesions, semiocclusive dress-
ings are contraindicated. In such cases, wet compresses
with sterile saline solution or Ringer-lactate solution and
alginate dressings are useful. Pain relief and improvement
of odor have also been observed with compresses [25].
Peristomal pyoderma gangraenosum in ulcerative colitis Figure 4
Peristomal pyoderma gangraenosum in ulcerative colitis.
Ecthyma-like pyoderma gangraenosum Figure 3
Ecthyma-like pyoderma gangraenosum.Orphanet Journal of Rare Diseases 2007, 2:19 http://www.OJRD.com/content/2/1/19
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For small flat lesions without secondary infection, topical
high potent corticosteroids are in use. They are rarely
capable of inducing remissions except in peristomal PG
[4,10,11]. Topical calcineurin inhibitors like tacrolimus
or pimecrolimus were used in some cases with success
[4,63,64]. Dramatic improvement has been observed in
particular in peristomal PG [65,66].
Surgical therapy
Surgery has to be used with caution since it can be trigger
PG [19]. Any surgical procedure has to be done as an
adjunct to immunosuppression only in patients with sta-
ble disease or partial remission. Autologous split-skin
grafts have been used with variable outcome [[67] Fig. 3].
A significant disadvantage of split-skin grafts is the neces-
sity to create a new wound at the donor site. New devel-
opments include the use of bioengineered skin, like the
dermal regeneration template Integra®, hair follicle stem
cell-derived autologous keratinocyte sheets Epidex®  or
hyaluronic acid-based autologous keratinocyte delivery
system Laserskin® [18,25,50,68-70]
Prognosis
Despite advances in management, the long term outcome
of PG remains unpredictable. We have seen one young
patient who did not respond to intense drug therapy any-
more. There fore because of intractable apin and toxicity
of the large wound a lower limb amputation was per-
formed eventually [Fig. 5]. Even in those patients who
respond to drug therapy relapses occur. They are seen in
about 70% of patients treated with prednisolone and 66%
of patients treated ciclosporine A [44]. In cases where long
term treatment is justified a careful monitoring of possible
adverse effects is mandatory [5,25]. In those cases with a
complete clinical remission the internal treatment dosage
should be tapered down. PG is still a potentially life-
threatening with a mortality rate of up to 30% in some
series [70].
Open questions
Our knowledge about pathogenesis and individual risk
factors for the development of PG is still rather limited.
This hampers the efforts for prevention. In the treatment
of PG controlled, prospective and randomized trials have
yet not been established. Such an approach would be pos-
sible only in a multinational trial because of the rareness
of this disease. It would further been limited by the vari-
ous clinical types and courses of this disease. A major
point for further investigations is the calculation of prog-
nosis. The course of this disease is unpredictable and the
manifestations range from very limited and superficial
ulcerations to widespread disease with extracutaneous
manifestations and life threatening course. The new
attempts of treatment with biologics needs careful investi-
gation since this could provide a new understanding of
the disease.
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